Sun Pharma API Division
✓ Verified SupplierMumbai, India · Export markets: US,EU,WHO
Verified since Aug 9, 2026
Products
3
Manufacturing sites
2
Sun Pharma API Division operates GMP-certified manufacturing facilities producing APIs and intermediates for regulated markets.
Regulatory history
No regulatory action on record
Sourced from openFDA and the EudraGMDP register — not self-declared by the supplier.
Nothing on record for this organisation.
Performance on PharmaLink
4 of 9 metrics have enough data
On-time delivery
Not enough data
No completed orders yet
Response rate
133%
8 of 6 inquiries
Answered within 24h
63%
5 of 8 answered inquiries
Quote win rate
25%
2 of 8 quotes submitted
Dispute rate
Not enough data
No completed orders yet
Repeat buyer rate
Not enough data
Only 1 buyers — too few to rate
Completed orders
0
On PharmaLink
Average order value
Not enough data
No completed orders yet
Time on PharmaLink
2m
Joined 2026-08-09
These measure activity on PharmaLink only, not the supplier’s whole business. Rates are withheld below five samples — one delivery on time is one delivery, not a 100% record.
Commercial terms
- Incoterms offered
- CIF · DAP · DDP · FOB · FOB MumbaiUsed on closed deals: FOB Mumbai
- Payment terms
- 30% advance, 70% against BL
- Standard lead time
- 2–3 weeks
- Lowest minimum order
- 25 kgAcross live listings; per-product MOQ may be higher.
- Samples
- Available on 1 listing(s)
- Cold chain
- ambient
Terms are supplier-stated defaults. The binding terms are the ones on a quote you accept.
Certifications
| Certifications | Status | Expiry | Source |
|---|---|---|---|
| US FDA GMP | ✓ | Apr 2028 | FDA drug database |
| EU GMP | ✓ | Sep 2026 | EudraGMDP |
| WHO PQ | ✓ | Feb 2029 | WHO PQ list |
| Manufacturing licence (Form 25/28) | ✓ | Aug 2029 | State FDA register |
Manufacturing facilities
| Site | FDA FEI | GMP standing | Last inspection | Capacity |
|---|---|---|---|---|
| Mumbai Unit-1Mumbai, India · manufacturing | 3002807546 | FDA Current (Active)EU Current (Active) | NAI (No Action Indicated)Sep 2025 | 2400 MT/year· 65% |
| Ankleshwar API Facility (Unit II)Ankleshwar, India · manufacturing | 3002808041 | FDA Current (Active) | VAI (Voluntary Action Indicated)Mar 2026 | 900 MT/year· 48% |
Regulatory filings
What your regulatory team can cite in a submission. Verify each number in the issuing authority's own register.
| Type | Number | Product | Status | Expiry |
|---|---|---|---|---|
| CEP (EDQM) | CEP 2019-021-3-0Open to reference | Paracetamol (Acetaminophen) | active | Aug 2026-34 days |
| US FDA ANDA | ANDA 200123 | Ibuprofen | expired | May 2026-144 days |
| US FDA Type II DMF | Type II DMF #23412Open to reference· 48 referencing | Paracetamol (Acetaminophen) | active | No expiry |
Key contacts
Sign in as a verified buyer to see business email addresses.
Mr. Suresh Kumar
Vice President - International API Exports · Global API Business
Dr. Meera Iyer
Head of Regulatory Affairs · Regulatory
Products
- 💊
Paracetamol (Acetaminophen)
CAS 103-90-2 · IP / BP / USP · MOQ 25 kg
$4.2–5.1/kg
- 💊
Ibuprofen
CAS 15687-27-1 · BP / USP · MOQ 25 kg
$6.1–7.4/kg
- 💊
Dicyandiamide (DCDA)
CAS 461-58-5 · Technical · MOQ 1000 kg
$2.8–3.2/kg
Reviews4.5(2)
- ★★★★★MediSource Global· Singapore
Strong quality, pricing negotiable
Good regulatory coverage; price came down after a short negotiation.
Regulatory complianceCommunication - ★★★★★Cipla Ltd· India✓ Verified buyer
Consistently reliable on Metformin
CoAs always in order and lead times as promised. Documentation is top-notch.
QualityDocumentationOn-time delivery